DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20220517

Treatment outcomes of patients with isoniazid resistant tuberculosis under National Tuberculosis Elimination Programme in Ahmedabad city: a retrospective study

Jatin G. Nagar, Kiran C. Rami, Meghna M. Patel, Kaushal M. Bhavsar

Abstract


Background: Drug resistance tuberculosis remains major public health problem worldwide. In India, the incidence of any isoniazid-resistant TB is 11.6% in new tuberculosis patients, while in previously treated patients, incidence is 25%. For isoniazid resistant cases management 6-9 months duration of H mono regimen containing rifampicin, pyrazinamide, ethambutol and levofloxacin is available under national tuberculosis elimination programme. We present a retrospective study on outcomes of patients of H mono regime in years 2019 and 2020 in Ahmedabad city.

Methods: Retrospectively we collected data about age, sex, co-morbid conditions, resistance level (high/low level isoniazid resistance) and treatment outcome of patients put on H Mono regimen under programme from January 2019 to December 2020 in Ahmedabad city from Ni-kshay, an online web-based portal.

Results: We have collected data of 251 patients (147 in 2019, 104 in 2020). Out of 251, 188 were males and 63 females. Out of 251, favourable outcome seen in 57.4% patients and unfavourable outcome seen in 42.6% patients. Favourable outcome was significantly higher among females compared to males.

Conclusions: Management of drug resistance tuberculosis according to drug sensitivity helps in better patient outcome. Early diagnosis of drug resistance and its treatment, timely diagnosis of treatment failure and management, better patient compliance and patient education about disease help in decrease in the unfavourable outcome.


Keywords


Tuberculosis, Isoniazid resistance, H mono regimen, Outcomes

Full Text:

PDF

References


World Health Organization. Global Tuberculosis Report 2021. Geneva, Switzerland: WHO, 2021. Available at: https://apps.who.int/iris/ handle/10665/346387. Accessed on 20 November 2021.

Chakaya J. Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts, International Journal of Infectious Diseases. 2021;1201-9712.

Dean AS, Zignol M, Cabibbe AM, Falzon D, Glaziou P, Cirillo DM, et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. PLoS Med. 2020;17(1):e1003008.

Ministry of health and family welfare, Government of India. Report of the first national anti-tuberculosis drug resistance survey: India 2014–16, New Delhi, India: Ministry of health and family welfare, Government of India, 2018. Available at: https://tbcindia.gov.in/showfile.php?lid=3315. Accessed on 20 November 2021.

Ministry of health and family welfare, Government of India. Guidelines on programmatic management of drug-resistant tuberculosis in India 2017. New Delhi, India: Ministry of health and family welfare, Government of India, 2017. Available at: https://tbcindia.gov.in/WriteReadData/Guideline%20for%20PMDT%20in%20India%202017.zip. Accessed on 21 November 2021.

Banerjee S, Siddiqi N, Hasnen S. Drug-resistant tuberculosis. In: Sharma S, ed. by. Tuberculosis. 2nd ed. New Delhi: Jaypee. 2009;388-90.

Ministry of health and family welfare, Government of India. Guidelines on programmatic management of drug-resistant tuberculosis in India 2019. New Delhi, India: Ministry of health and family welfare, Government of India. 2019.

World health Organization. The end TB strategy. World health Organization. Geneva, Switzerland: WHO, 2015. Available at: https://app s.who.int/iris/handle/10665/33126. Available at: 20 November 2021.

Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis. 2011;53(4):369-72.

Garcia CJG, Alarco´nGuizado VA, Ticona MA, Alarcon E, Heldal E, Moore DAJ. Treatment outcomes for isoniazid mono resistant tuberculosis in Peru, 2012-2014. PLoS ONE. 2018;13(12):e0206658.

Bachir M, Guglielmetti L, Tunesi S, Billard-Pomares T, Chiesi S, Jaffré J et al. Isoniazid Resistance Group. Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events. Int J Infect Dis. 2021;107:86-91.

Chien JY, Chen YT, Wu SG, Lee JJ, Wang JY, Yu CJ. Treatment outcome of patients with isoniazid mono-resistant tuberculosis. Clin Microbiol Infect. 2015;21(1):59-68.

Ministry of health and family welfare, Government of India. Guidelines for programmatic management of drug-resistant tuberculosis in India 2021. New Delhi, India: Ministry of health and family welfare, Government of India, 2021. Available at: https://tbcindia.gov.in/showfile.php?lid=3590. Accessed on 20 November 2021.